Web
Please enter a search for web results.
News
BioMed X Announces New Neuroscience Research Collaboration in the USA
1+ hour, 38+ min ago (199+ words) BioMed X Announces New Neuroscience Research Collaboration in the USA NEW HAVEN, CT, USA, November 25, 2025 / Biotech Newswire / --BioMedX, a leading external innovation hub for pharma, announced today the launch of a new collaborative research project with AbbVie, hosted at the BioMed X Institute in New Haven, Connecticut. The focus of this collaboration will be on the identification of specific mechanisms that underpin this debilitating symptom, using patient-derived data to validate mechanistic insights wherever possible. Mark Johnston, CEO of BioMed X USA, commented: "Partnering with AbbVie on this new anhedonia project allows us to combine expertise in neuroscience, molecular biology, and clinical translation. Together, we aim to tackle the fundamental mechanisms of anhedonia, which could have profound implications for the treatment of depression and other related disorders." This represents the third research project in the collaboration between BioMed X and AbbVie,…...
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
11+ hour, 25+ min ago (147+ words) Beyond the EU, Dupixent is also approved for CSU in certain adults and adolescents in several countries including the US and Japan. About the Dupixent CSU phase 3 study program The primary endpoint in all three studies assessed the change from baseline in itch and hives (weekly urticaria activity score [UAS7], 0-42 scale). The key secondary endpoint (also assessed at 24 weeks) was change from baseline in itch (measured by the weekly itch severity score, 0-21 scale). Additional secondary endpoints assessed at 24 weeks evaluated: The results from Studies A and B were published in The Journal of Allergy and Clinical Immunology. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation....
Why Orange County Patients Frequently Choose Dr. Rubinstein for Facial Plastic Surgery
17+ hour, 36+ min ago (98+ words) With more than two decades serving the region, Laser & Cosmetic Surgery Specialists offers Orange County residents comprehensive facial assessments and treatment planning, emphasizing long-term balance and individualized guidance. A Facial Plastic Surgery Practice Serving Orange County for Over 20 Years Facial Surgery Options for Patients Across Orange County Non-Surgical Facial Treatments for Patients in Orange County A Convenient Location for Orange County Residents Individualized Care and a Focus on Long-Term Facial Results A Trusted Option for a Range of Facial Concerns About Laser & Cosmetic Surgery Specialists, PC SOURCE: Laser & Cosmetic Surgery Specialists...
Richmond Pharmacology Marks Five Years Since the World’s First Intravenous CRISPR Treatment
1+ day, 5+ hour ago (587+ words) Now, that first patient,Ann Deeganfrom Ballinagore, Ireland, and another early Nex-Z recipient,James Greenfrom Burt, Donegal, have spoken publicly for the first time to describe how gene editing transformed their experience of suffering from hereditary amyloidosis (ATTR), a disease from which they had both seen family members die. Ann and James appeared at London Life Sciences Week alongsideDr J'rg Taubel, Richmond Pharmacology's CEO and founder, leader of the 2020 landmark clinical trial that ushered in a new era of medicine. A new chapter for patients Ann Deegan, a retired nurse, was diagnosed in 2019 withATTR-PN, a hereditary form of amyloidosis that causes misfolded proteins to build up around the nerves. She said: "My brother was diagnosed in 2016 and was told to go home and get his affairs in order. There was nothing they could do. I've been so, so lucky and…...
TRNR Updates Investor FAQs; Highlights Newly Published Q3 Shareholder Letter
4+ day, 2+ hour ago (901+ words) AUSTIN, TEXAS / ACCESS Newswire / November 21, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the Wattbike, CLMBR and FORME brands and pending acquirer of Sportstech, today announced that it has updated the Investor FAQ section of its website to address shareholder questions related to the Company's most recent quarterly filing, timing of the Sportstech acquisition, and 2025 pro forma revenue expectations of more than $80 million.This update follows the Company's Q3 2025 shareholder letter, published yesterday, which provided a detailed narrative on TRNR's operating progress, integration milestones and pro forma performance. As the letter noted, "Q3 marked a pivotal step forward for Interactive Strength. It... TRNR Updates Investor FAQs; Highlights Newly Published Q3 Shareholder Letter AUSTIN, TEXAS / ACCESS Newswire / November 21, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the Wattbike,…...
ClearPoint Neuro Completes Acquisition of IRRAS
4+ day, 23+ hour ago (894+ words) Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 20, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has completed its previously announced acquisition of IRRAS Holdings, Inc. ("IRRAS"). The transaction closed on November 20, 2025 following receipt of IRRAS shareholder approval and satisfaction or waiver of all required closing conditions.Under the terms of the merger agreement previously announced, the Company paid $5.0 million in cash and issued 1,325,000 shares of its common stock... ClearPoint Neuro Completes Acquisition of IRRAS Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 20, 2025 / ClearPoint Neuro,…...
Who is the best Rhinoplasty Surgeon in Seattle?
4+ day, 23+ hour ago (487+ words) The best rhinoplasty in Seattle is by Dr. Sajan Each rhinoplasty procedure in Dr. Sajan's practice begins with a detailed evaluation of nasal anatomy, breathing function, and facial proportions. Surgical plans are tailored to patient goals rather than standardized templates, an approach reflecting current trends toward personalized medicine in aesthetic and reconstructive surgery. Dr Sajan's mastery of modern Rhinoplasty techniques Dr. Sajan offers a complete suite of rhinoplasty techniques and selects the least invasive, most effective path for each patient: Preservation Rhinoplasty: Focuses on refining the nasal profile while preserving natural bone and cartilage. This method minimizes structural disruption and maintains the integrity of the nasal framework, resulting in stable, natural-looking contours. Structural Rhinoplasty: Encompasses procedures that reshape or reinforce nasal support structures while maintaining long-term stability. Depending on each patient's needs, Dr. Sajan performs either a closed or open…...
The Best Networking Strategies for Senior Professionals in Life Sciences
5+ day, 5+ hour ago (379+ words) Senior professionals in the life sciences must approach networking with strategic intention; not simply exchanging business cards. First, clarify your goals: Are you looking for new collaborations, mentorship, or insights into emerging sectors? Effective networking starts with preparation. Research events, identify key attendees, and craft a concise elevator pitch that clearly reflects your expertise and objectives. Leverage both in'person and online channels. Attend conferences and workshops to connect face'to'face; engage on platforms like LinkedIn by optimising your profile, joining relevant groups, and sharing meaningful content. Cultivate true relationships: listen actively, show genuine interest in others" work, and offer value proactively. Follow up after meetings with personalis... The Best Networking Strategies for Senior Professionals in Life Sciences Senior professionals in the life sciences must approach networking with strategic intention; not simply exchanging business cards. First, clarify your goals: Are you looking…...
Matexcel Expands Copper‑Alloy Powder Portfolio to Support Advanced Materials Applications
5+ day, 6+ hour ago (516+ words) Matexcel, a materials technology company specializing in advanced powders and alloys, today announced an updated line of Cu'based metal powders, strengthening its portfolio of copper'alloy materials. The new offering is intended to support industries such as aerospace, automotive, electronics, additive manufacturing and biomedical engineering with higher'performance copper alloy powder tailored for specific applications. Copper based metal powders play a critical role in a wide variety of technical applications. Their combination of excellent thermal and electrical conductivity, good machinability, and compatibility with powder'metallurgy and additive'manufacturing routes make them a go'to material for components like electrical contacts, heat'exchangers, and 3D'printed metal parts. As... Matexcel Expands Copper'Alloy Powder Portfolio to Support Advanced Materials Applications Matexcel, a materials technology company specializing in advanced powders and alloys, today announced an updated line of Cu'based metal powders, strengthening its portfolio of copper'alloy materials. The new offering…...
Concept Life Sciences Presents New Data Advancing Neuroinflammation and Neurodegeneration Research at Neuroscience 2025
5+ day, 12+ hour ago (141+ words) 1. Development of a Drug Screening Cascade to Identify Novel Potent and Selective NLRP3 Inhibitors 2. In-Vitro Models of OPC Maturation and Myelination for Drug Discovery The poster can be accessed [here]. Dr. Elise Malavasi, Neuroscience Associate Director at Concept Life Sciences, commented: "Our work, presented at Neuroscience 2025, highlighted how our integrated biology platforms enable a deeper understanding of neuroinflammatory and neurodegenerative mechanisms. By combining advanced human cell systems, primary cell-based assays, and 3D models, we provide our partners with translational tools that de-risk discovery and accelerate progress toward clinical impact." New white paper: Building a complete picture of inflammasome activity Ahead of its presentations at Neuroscience 2025, Concept Life Sciences launched a new white paper entitled "Advancing Inflammasome Drug Discovery: Building a Complete Picture of Inflammasome Activity for Therapeutic Success." The white paper can be accessed'here....